Rilpivirine is associated with a good efficacy and safety profile. However, data from real-life settings are scarce. Methods: We investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral therapy in a prospective, observational, multicenter study. Results: We enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4± 10.5 years, mean CD4 600± 327 cell/μL, mean HIV-RNA 3.80± 1.15 log10 cp/mL. After a median follow up of 16 months, 81 (16.2%) interruptions were reported, 36 (7.2%) of which for adverse events (16 of grade ≥3), most commonly neurological and gastrointestinal. We observed virological failures in only 8 (1.6%) patients. Naive patients showed a significant reduction in eGFR at week 24, 48 and 72 and in total cholesterol (TC)/HDL ratio at week 48 (p=0.007). In patients switching from PI we found a significant decrease at week 24 and 48 in TC and triglycerides at week 24, 48 and 72. eGFR showed a significant decrease at week 48 and 72. TC/HDL ratio showed a statistically significant decrease at week 24 (p=0.0008) and 72 (p=0.04). A significant increase at week 24 and 48 in AST and ALT values was observed. Patients switching from TDF/FTC/EFV showed a reduction in HDL, total cholesterol and triglycerides at week 24 and 48 and in eGFR at all follow up times. TC/HDL ratio showed a significant decrease at week 48 (p=0.01). CDC stage C and antiretroviral-experience (especially Protease Inhibitors) were associated with RPV discontinuation. Conclusion: In conclusion, our data confirm Rilpivirine efficacy, safety and tolerability with improvement in lipid profile. Although hepatic and renal events rarely caused discontinuation, liver and kidney parameters should be monitored.

Bagella, P., De Socio, G., Ricci, E., Menzaghi, B., Martinelli, C., Squillace, N., et al. (2018). Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project. INFECTION AND DRUG RESISTANCE, 11, 615-623 [10.2147/IDR.S152090].

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project

Squillace N.;Bonfanti P.;
2018

Abstract

Rilpivirine is associated with a good efficacy and safety profile. However, data from real-life settings are scarce. Methods: We investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral therapy in a prospective, observational, multicenter study. Results: We enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4± 10.5 years, mean CD4 600± 327 cell/μL, mean HIV-RNA 3.80± 1.15 log10 cp/mL. After a median follow up of 16 months, 81 (16.2%) interruptions were reported, 36 (7.2%) of which for adverse events (16 of grade ≥3), most commonly neurological and gastrointestinal. We observed virological failures in only 8 (1.6%) patients. Naive patients showed a significant reduction in eGFR at week 24, 48 and 72 and in total cholesterol (TC)/HDL ratio at week 48 (p=0.007). In patients switching from PI we found a significant decrease at week 24 and 48 in TC and triglycerides at week 24, 48 and 72. eGFR showed a significant decrease at week 48 and 72. TC/HDL ratio showed a statistically significant decrease at week 24 (p=0.0008) and 72 (p=0.04). A significant increase at week 24 and 48 in AST and ALT values was observed. Patients switching from TDF/FTC/EFV showed a reduction in HDL, total cholesterol and triglycerides at week 24 and 48 and in eGFR at all follow up times. TC/HDL ratio showed a significant decrease at week 48 (p=0.01). CDC stage C and antiretroviral-experience (especially Protease Inhibitors) were associated with RPV discontinuation. Conclusion: In conclusion, our data confirm Rilpivirine efficacy, safety and tolerability with improvement in lipid profile. Although hepatic and renal events rarely caused discontinuation, liver and kidney parameters should be monitored.
Articolo in rivista - Articolo scientifico
Cohort study; Combination antiretroviral therapy; Experienced patients; HIV-1; Naive; NNRTI;
Cohort study; Combination antiretroviral therapy; Experienced patients; HIV-1; Naive; NNRTI
English
615
623
9
Bagella, P., De Socio, G., Ricci, E., Menzaghi, B., Martinelli, C., Squillace, N., et al. (2018). Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project. INFECTION AND DRUG RESISTANCE, 11, 615-623 [10.2147/IDR.S152090].
Bagella, P; De Socio, G; Ricci, E; Menzaghi, B; Martinelli, C; Squillace, N; Maggi, P; Orofino, G; Calza, L; Carenzi, L; Celesia, B; Penco, G; Di Biagio, A; Valsecchi, L; Vichi, F; Colombo, V; Parruti, G; Dentone, C; Falasca, K; Bonfanti, P; Madeddu, G
File in questo prodotto:
File Dimensione Formato  
IDR-152090-efficacy--durability-and-safety-of-rilpivirine-in-clinical-p_042418.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 468.58 kB
Formato Adobe PDF
468.58 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/276421
Citazioni
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 12
Social impact